Results 181 to 190 of about 155,912 (356)

Ear disease in Aboriginal and Torres Strait Islander children [PDF]

open access: yes
This resource sheet reviews past and current programs, research and strategies (both government and non-government) for the prevention and treatment of ear disease in Indigenous children.

core  

Liquid Biopsies in Head and Neck Cancers: Recent Developments Across Biofluids, Analytes, and Molecular Features

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Head and neck cancers (HNCs) are too often diagnosed at advanced stages when outcomes are poor. Additionally, robust tools for the early detection of recurrence remain elusive. These gaps drive interest in so‐called liquid biopsy approaches for HNC detection, prognostication, and surveillance.
Patricia J. Brooks, Scott V. Bratman
wiley   +1 more source

The Need for Vestibular Implants in a Tertiary Referral Ear, Nose, and Throat Center and Its Relation to Hearing Status. [PDF]

open access: yesJ Int Adv Otol, 2023
Sluydts M   +8 more
europepmc   +1 more source

Ear, Nose and Throat

open access: yesInternational Journal of Clinical Practice, 1966
openaire   +2 more sources

Oncological Impact of Surgical Margin Status After Transoral Laser Microsurgery for Early Glottic Cancer

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Transoral laser microsurgery is a well‐established treatment for early glottic cancer. However, managing patients with close/positive margins remains debated. This study analyzes the relationship between resection margins and oncologic outcomes.
Sae Hatomi   +4 more
wiley   +1 more source

Diseases of the Ear, Nose, and Throat [PDF]

open access: yesAnnual Review of Medicine, 1950
Walter E. Loch   +2 more
openaire   +3 more sources

Safety and Efficacy Findings From a Phase Ib/II Study of ASP‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 ...
David M. Cognetti   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy